Exciting Opportunities for Sitryx Therapeutics
Oxford, UK and Boston, MA – Sitryx Therapeutics, a pioneering name in the biopharmaceutical landscape, is poised to participate in two significant investor conferences that focus on innovation in healthcare. This company specializes in developing novel oral therapies aimed at restoring immune balance in those battling autoimmune and inflammatory diseases.
Upcoming Conferences to Attend
Sitryx will be represented at the following events:
Wells Fargo Virtual Private Biotech Symposium
The participation in this symposium is set for November 5, 2025. Investors will have the opportunity to engage in 1x1 meetings, which is an excellent chance for personalized discussions about the company’s innovative approaches to drug development.
Stifel 2025 Healthcare Conference
A week later, on November 12, 2025, Sitryx will attend the Stifel 2025 Healthcare Conference in New York. This event will feature a presentation along with the opportunity for 1x1 meetings. The presentation is scheduled for 8:00 AM ET, promising insights into the company's cutting-edge research and future prospects.
Meetings and Engagements
The management team of Sitryx is eager to engage with prospective investors through one-on-one meetings and group discussions at both events. For those interested in scheduling discussions, reaching out to their Wells Fargo and Stifel representatives would be the best course of action.
Webcast Availability
For those who cannot attend in person, a webcast of the Stifel presentation will be available, ensuring that all interested stakeholders can access the valuable insights shared during the event. Keep an eye on the company’s Events page to find out more about this offering.
About Sitryx Therapeutics
Sitryx is recognized for its commitment to developing transformative therapies for autoimmune and inflammatory conditions. The company is advancing a robust pipeline filled with novel small molecule candidates targeting conditions that present significant challenges in treatment options. Among these candidates is SYX-5219, a groundbreaking oral therapy designed to act as a PKM2 modulator and aimed at addressing atopic dermatitis.
Since its establishment in 2018, with initial funding from SV Health Investors, Sitryx has built an impressive portfolio of specialist investors, including prominent names like Sofinnova Partners, Oxford Science Enterprises, Longwood Fund, Eli Lilly and Company, and GSK. These partnerships bolster the company’s mission and enhance its capacity for bringing life-changing treatments to market.
With its headquarters in Oxford and additional presence in Boston, MA, Sitryx continues to expand its footprint in the industry, driven by a passion for innovation and a determination to meet the needs of patients worldwide.
Frequently Asked Questions
1. What is the focus of Sitryx Therapeutics?
Sitryx focuses on developing novel oral therapies targeting autoimmune and inflammatory diseases.
2. Which conferences is Sitryx participating in?
Sitryx will attend the Wells Fargo Virtual Private Biotech Symposium and the Stifel 2025 Healthcare Conference.
3. When is the Stifel conference presentation scheduled?
The Stifel conference presentation is scheduled for November 12, 2025, at 8:00 AM ET.
4. How can investors schedule meetings with Sitryx?
Investors can contact their Wells Fargo and Stifel representatives to schedule one-on-one meetings with Sitryx management.
5. Where can I find more information about Sitryx?
For more details, please visit Sitryx's official website.
